In addition to launching a special project team to explore new therapies, Octapharma has joined a global alliance to investigate development of a hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19. This collaboration, called the CoVIg-19 Plasma Alliance, will leverage leading-edge expertise and work that companies including Octapharma, CSL, Takeda, BPL, Biotest, LFB, ADMA Biologies, BioPharma Plasma, GC Pharma and Sanquin have underway. The Bill and Melinda Gates Foundation is providing advisory support, with Microsoft providing assistance with technology. Experts from the alliance are collaborating on key elements of a solution such as plasma collection, clinical trial development and commercial-scale manufacturing, working together to bring a successful medication to market as quickly as possible.
Developing a hyperimmune immunoglobulin therapy will require plasma donation from many individuals who have fully recovered from COVID-19, and whose blood contains antibodies that can fight the disease caused by the novel coronavirus (SARS-CoV-2). We need to collect this “convalescent” plasma from as many donors as possible, as soon as possible.
Are you eligible to donate? If you had a confirmed case of COVID-19, and your doctor has confirmed that you have fully recovered and are no longer contagious, we encourage you to contact your nearest plasma collection center or the CoVIg-19 Plasma Alliance.
Not eligible to donate? There are other ways to participate in developing an effective treatment for the coronavirus pandemic.
Learn more about the CoVIg-19 Plasma Alliance, donating your plasma, and other ways to participate.